Inactive Instrument

News InMed Pharmaceuticals Inc. Toronto S.E.

Equities

IN

CA4576376012

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer's Expert, to the Company's Scientific Advisory Board	Apr. 18	NE
InMed Pharmaceuticals Inc. Appoints David G. Morgan to its Scientific Advisory Board	Apr. 17	CI
InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration	Apr. 16	NE
InMed Pharmaceuticals Inc. Announces Additional Preclinical Data Demonstrating INM-901'S Positive Pharmacological Effects in the Potential Treatment of Alzheimer's Disease	Apr. 04	CI
InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies	Apr. 04	NE
InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance	Mar. 20	NE
InMed Pharmaceuticals Inc. Provides Update on Pharmaceutical Development Programs	Feb. 13	CI
InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update	Feb. 13	NE
InMed Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Feb. 13	CI
InMed Pharmaceuticals Inc. Announces Chief Financial Officer Changes, Effective February 20, 2024	Feb. 09	CI
InMed Pharmaceuticals Inc. Announces Executive Changes, Effective February 20, 2024	Feb. 09	CI
InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer	Feb. 09	NE
Transcript : InMed Pharmaceuticals Inc. - Special Call	Jan. 25
InMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ET	Jan. 18	NE
InMed Pharmaceuticals Provides Business Update and Milestones for 2024	Jan. 16	NE
InMed Announces Results of 2023 Annual General Meeting	Dec. 19	NE
Transcript : InMed Pharmaceuticals Inc. - Shareholder/Analyst Call	Dec. 19
Inmed Pharmaceuticals Inc. Announces the Launch of Inm-089	Nov. 29	CI
InMed Expands its Pharmaceutical Pipeline with INM-089 targeting the treatment of Age-Related Macular Degeneration	Nov. 29	NE
InMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business Update	Nov. 14	NE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News InMed Pharmaceuticals Inc. Toronto S.E.

Equities

IN

CA4576376012

Summary

Filters